Virios Therapeutics
Biotechnology ResearchGeorgia, United States2-10 Employees
Dogwood Therapeutics is a development-stage biotechnology company focused on advancing novel therapeutics for pain and neuropathy. The company is currently pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing SP16, a first-in-class LRP1 agonist, projected to enter a phase 1b chemotherapy induced neuropathy study fully funded by the National Cancer Institute.